Epstein-Barr virus DNA-guided chemoradiotherapy for patients with low-risk locoregionally advanced nasopharyngeal carcinoma: a secondary 5-year follow-up analysis of an open-label, randomised controlled, phase 2 non-inferiority trial.

ABSTRACT:

Background

Intensity-modulated radiation therapy (IMRT) with two cycles of concurrent 100 mg/m² cisplatin (DDP) presents a potential alternative for low-risk, locoregionally advanced nasopharyngeal carcinoma (LA-NPC). This study assessed its long-term survival outcomes and late toxicities.

Methods

This is a secondary analysis of an open-label, randomised, controlled, phase 2 non-inferiority trial, which enrolled patients with low-risk LA-NPC (pretreatment plasma Epstein-Barr virus DNA < 4000 copies/mL) at Sun Yat-sen University Cancer Center. Eligible participants were randomly assigned (1:1) to receive either two cycles or three cycles of concurrent cisplatin (100 mg/m² every 3 weeks) with intensity-modulated radiation therapy. The primary endpoint was

SUBMITTER: Li YC 

PROVIDER: S-EPMC12615317 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature